JB/CALL/MODERNA/150/0.0166/20.12.24 | Market Closed - Swiss Exchange 16:20:00 27/06/2024 BST | ||
| 0.16 CHF | -27.27% |
|
| Current month | -57.89% | ||
| 1 month | -72.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 0.16 | -27.27% |
| 26/06/24 | 0.22 | -15.38% |
| 20/06/24 | 0.26 | +8.33% |
| 19/06/24 | 0.24 | -4.00% |
Delayed Quote Swiss Exchange
Last update June 27, 2024 at 04:20 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Bank Julius Bär |
| MRNFJB | |
| ISIN | CH1276781080 |
| Date issued | 27/07/2023 |
| Strike | 150 $ |
| Maturity | 20/12/2024 (174 Days) |
| Parity | 60 : 1 |
| Emission price | 0.34 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.59 CHF |
|---|---|
| Lowest since issue | 0.06 CHF |
| Spread | 0.01 CHF |
| Spread % | 6.25% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.8
USD
Average target price
145.9
USD
Spread / Average Target
+22.82%
- Stock Market
- Warrants
- MRNFJB Warrant
